Trial Profile
Genetic Polymorphism oriented Phase II Study of Irinotecan and Doxifluridine for Unresectable or Recurrent Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 May 2016
Price :
$35
*
At a glance
- Drugs Doxifluridine (Primary) ; Irinotecan (Primary)
- Indications Colorectal cancer
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms FRUTIRI
- 11 Feb 2011 New trial record